Neue Diagnostik- und Therapiestrategien bei aggressiven Lymphomen

Die Non-Hodgkin-Lymphome (NHL) umfassen eine klinisch, biologisch und pathohistologisch heterogene Gruppe von Erkrankungen, deren gemeinsames Merkmal die Abstammung von Zellen des lymphatischen Systems ist. Etwa 40 % aller Lymphome gehören zur klinisch und histopathologisch heterogenen Gruppe der sog. aggressiven Lymphome [2], die durch ein äußerst rasches Wachstum und eine hohe Proliferationsrate gekennzeichnet - aber gerade wegen dieser Eigenschaft durch optimierte Chemotherapieregimes heilbar sind.

Wesentliche, in den letzten 5 Jahren erreichte Neuerungen in Diagnostik und Therapie dieser Lymphome betreffen

die Einführung einer biologisch fundierten, weltweit akzeptierten Klassifikation der Lymphome durch die Weltgesundheitsorganisation WHO 31, die Identifikation der genetischen Basis der Heterogenität durch die Genexpressionsanalyse mit genomweiten Chip-Analysen 25, die signifikante Verbesserung der Heilungsrate durch dosisdichte Chemotherapieschemata 21, die signifikante Verbesserung der Heilungsrate durch die kombinierte Chemo-Immuntherapie mit monoklonalen Antikörpern 6.

Literatur

• 1 Alizadeh A A, Eisen M B, Davis R E. et al . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.  Nature. 2000;  403 503-511
• 2 Anderson J R, Armitage J O, Weisenburger D D. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project.  Ann Oncol. 1998;  9 717-720
• 3 Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project.  J Clin Oncol. 1998;  16 2780-2795
• 4 Canellos G P, Skarin A T, Klatt M M. et al . The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.  Semin Hematol. 1987;  24 2-7
• 5 Coiffier B, Ferme F, Hermine O. et al . Rituximab plus CHOP (CHOP-R) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study (abstract).  Blood. 2001;  97 405
• 6 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP Alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
• 7 Fisher R I, Gaynor E R, Dahlberg S. et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.  New Engl Journ Med. 1993;  328 1002-1006
• 8 Fisher R I, Longo D L, DeVita V T. et al . Long-term follow up of ProMACE-CytaBOM in non-Hodgkin’s lymphomas.  Ann Oncol. 1991;  2 S33-S35
• 9 Gianni A M, Bregni M, Siena S. et al . High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.  N Engl J Med. 1997;  336 1290-1297
• 10 Glass B, Kloess M, Engert A. et al . Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (Mega-CHOEP) in primary treatment of aggressive lymphoma: Dose intensity count (Abstract).  Bone Marrow Transpl. 2004;  (Suppl 1) O103s
• 11 Habermann T M, Weller E, Horning S J. Rituximab-CHOP vs CHOP with a second randomization to maintenance rituximab or observation in patients > 60 years with diffuse large B-cell lymphoma (DLBCL) (abstract).  Blood. 2004;  102 233
• 12 Haioun C, Lepage E, Gisselbrecht C. et al . Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87 - 2 protocol - a Groupe d’Etude des Lymphomes de l’Adulte study.  J Clin Oncol. 2000;  18 3025-3030
• 13 Hans C P, Weisenburger D D, Greiner T C. et al . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.  Blood. 2004;  103 275-282
• 14 Kaiser U, Uebelacker I, Abel U. et al . Randomized study to evaluate the use of high-dose therapy as part of primary treatment for „aggressive” lymphoma.  J Clin Oncol. 2002;  20 4413-4419
• 15 Klimo P, Connors J M. Updated clinical experience with MACOP-B.  Semin Hematol. 1987;  24 26-34
• 16 Kluin-Nelemans H C, Zagonel V, Anastasopoulou A. et al . Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study.  J Nat Cancer Inst. 2001;  93 22-30
• 17 McKelvey E M, Gottlieb J A, Wilson H E. Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphomas.  Cancer. 1976;  38 1484-1493
• 18 Milpied N, Deconinck E, Gaillard F. et al . Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.  N Engl J Med. 2004;  350 1287-1295
• 19 Mounier N, Briere J, Gisselbrecht C. et al . Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).  Blood. 2003;  101 4279-4284
• 20 Pfreundschuh M, Trumper L, Kloess M. et al . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.  Blood. 2004;  104 626-633
• 21 Pfreundschuh M, Trumper L, Kloess M. et al . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.  Blood. 2004;  104 634-641
• 22 Pfreundschuh M, Trümper L, Ma D. et al . Randomized intergroup trial of first line treatment for patients below 60 years with diffuse large B-cell lymphoma with a CHOP-like regimen with or without the anti-CD 20 antibody rituximab - early stopping after the first interim analysis (abstract).  J Clin Oncol. 2004;  23 556
• 23 Philip T, Guglielmi C, Somers R. et al . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma [abstract].  New Engl Journ Med. 1995;  333 1540-1545
• 24 Reyes F, Lepage E, Munck J N. et al . Superiority of the ACVBP regimen over a combined treatment with three cycles of CHOP followed by involved field radiotherapy in patients with low risk localized agressive non-Hodgkin’s lymphoma: Results of the LNH93 - 1 study (abstract).  Blood. 2000;  96 532a
• 25 Rosenwald A, Wright G, Chan W C. et al . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 1937-1947
• 26 Santini G, Salvagno L, Leoni P. et al . VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group.  J Clin Oncol. 1998;  16 2796-2802
• 27 Shipp M A, Harrington D P. et al . The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma.  New Engl J Med. 1993;  329 987-994
• 28 Shipp M A, Ross K N, Tamayo P. et al . Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.  Nat Med. 2002;  8 68-74
• 29 Stansfield A G, Diebold J, Noel H. et al . Kiel Classification.  Lancet. 1988;  1 292-293
• 30 Verdonck L F, van Putten W L, Hagenbeek A. et al . Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma.  N Engl J Med. 1995;  332 1045-1051
• 31 WHO .Tumours of Haemotopoietic and Lymphoid Tissue. 1 ed Lyon: IARC Press 2001